Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EBT (2016 - 2026)

Cytosorbents filings provide 15 years of EBT readings, the most recent being -$6.5 million for Q4 2025.

  • On a quarterly basis, EBT fell 363.94% to -$6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$15.8 million, a 49.85% decrease, with the full-year FY2025 number at -$9.6 million, up 10.1% from a year prior.
  • EBT hit -$6.5 million in Q4 2025 for Cytosorbents, down from -$3.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $14.5 million in Q4 2023 to a low of -$12.2 million in Q3 2022.
  • Median EBT over the past 5 years was -$5.4 million (2021), compared with a mean of -$4.7 million.
  • Biggest five-year swings in EBT: plummeted 662.9% in 2021 and later surged 881.47% in 2023.
  • Cytosorbents' EBT stood at -$10.0 million in 2021, then skyrocketed by 81.49% to -$1.9 million in 2022, then surged by 881.47% to $14.5 million in 2023, then tumbled by 83.03% to $2.5 million in 2024, then crashed by 363.94% to -$6.5 million in 2025.
  • The last three reported values for EBT were -$6.5 million (Q4 2025), -$3.6 million (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.